TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($21.28) EPS for the quarter, FiscalAI reports.
TransCode Therapeutics Trading Down 2.8%
NASDAQ RNAZ opened at $6.60 on Friday. The stock’s 50 day moving average is $8.58 and its 200 day moving average is $8.96. TransCode Therapeutics has a 12 month low of $6.08 and a 12 month high of $20.99. The stock has a market cap of $6.07 million, a PE ratio of -0.13 and a beta of 1.39.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, TransCode Therapeutics has a consensus rating of “Sell”.
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
See Also
- Five stocks we like better than TransCode Therapeutics
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
